Introduction {#S1}
============

Varieties of microbial communities are dominant throughout the human different body niches including skin, mouth, respiratory tract, throat, stomach, gut and colon, which mainly compose of bacteria, protozoa, archaeon, viruses, and fungi ([@B35]; [@B2]). It is generally that a wide range of them play fundamental roles in human health and diseases such as maintaining homeostasis ([@B3]), developing the immune system ([@B45]; [@B18]) and resisting pathogens ([@B35]). For example, the majority of microbes reside in the gut, regulating human physiology and nutrition by modulating host metabolism and immunity. They can digest and convert dietary constituents into active forms ([@B40]; [@B1]).

Microbial communities are considered as an essential "organ" governing health and disease, which can be influenced by host genetics and host environment such as feeding habits, life styles, seasons and antibiotics ([@B23]; [@B2]). If the microbial communities become imbalanced, there may interfere with the symbiotic relationships and cause diseases. For instance, researchers found that the number of phylum Actinobacteria among diabetics was significantly lower than the healthy person ([@B30]). In addition, some studies found a decrease in the relative percentage of Bacteroidetes in obese people compared to the general population ([@B27]). Moreover, low microbial diversity can lead to inflammatory bowel disease (IBD) ([@B40]). Thus, understanding the microbe-disease associations can help us know disease pathogenesis to boost disease diagnosis and therapy.

With the advances in sequencing technologies and bioinformatics, more and more microbes living in oceans, soil, human bodies and elsewhere began to be investigated by the scientific community ([@B17]; [@B35]; [@B8]). The Human Microbiome Project Consortium (HMP) was funded to explore the relationships between microbes and human diseases. It generates a wide range of quality-controlled resources and data to develop metagenomic protocols, which is available for scientific research ([@B35]). [@B31] constructed The Human Microbe-Disease Association Database (HMDAD) through collecting correlations between microbes and diseases from 61 published literatures. These achievements provided the foundation for further research on using computational methods to predict potential associations.

In recent years, some computational methods have been conceived for predicting microbe-disease associations based on the assumption that similarly functioning microorganisms incline to share similar associations or non-associations with diseases. By using the Gaussian interaction profile (GIP) kernel similarity, [@B9] developed a prediction method called KATZHMDA that infers potential associations based on the number and length of walks in a heterogeneous network. [@B28] constructed a bidirectional weighted network by combining a normalized Gaussian interaction scheme with a bidirectional recommendation model. [@B59] used a bi-random walk and logistic function transformation on a heterogeneous network constructed based on the GIP kernel similarity. Through a combination of the GIP kernel similarity and LapRLS classification, [@B53] designed a computing model LRLSHMDA, which is semi-supervised. Meanwhile, through integrating the GIP kernel similarity with disease symptom similarity, [@B41] implemented the matrix decomposition and label propagation algorithm on the similarity network for associations' prediction. [@B22] predicted potential associations based on known microbe-disease bipartite graph and neighbor collaborative filtering. Moreover, [@B15] proposed a method called MDPH_HMDA for prediction by executing standardized HeteSim measurements to weight the relations in a heterogeneous network combined by the GIP kernel similarity, the microbe--microbe functional similarity and the symptom-based human disease similarity. [@B38] identified the potential associations by introducing the concept of hypergraph, which put all disease-related microbes on a single hyperedge. In order to take the unequal contributions of microbe and disease information into consider, [@B57] developed a bidirectional similarity integral label propagation method with calculating the microbe functional similarity and the disease semantic similarity.

At the same time, many network embedded methods have been proposed, such as DeepWalk ([@B39]), SDNE ([@B52]), Node2vec ([@B19]), etc. In this study, inspired by the performance of graph representations for many real-world problems such as protein network research, text and visual processing ([@B5]). We utilize Node2vec ([@B19]) to predict potentially unknown associations (LGRSH) on a heterogeneous network. First, similarity networks for microbes and diseases are calculated by the GIP kernel similarity. Then, we construct a heterogeneous network integrating the two similarity networks and known microbe-disease associations' network. After that, the embedding algorithm Node2vec has been utilized to assign a low-dimensional vector representation to nodes in the heterogeneous network. Finally, according to the vector representation of each node, we calculate the degrees of correlation between microbes and diseases to discover potential associations with a modified rule-based inference method. In order to assess the prediction performance of LGRSH, we implemented Leave-one-out cross validation (LOOCV) and fivefold cross validation. The area under the receiver operating characteristic curve (AUC) obtained by LGRSH are 0.9260 and 0.9254, which is better than the compared methods. Moreover, case studies of asthma, Chronic Obstructive Pulmonary Disease (COPD) and IBD demonstrate that LGRSH can be considered as an effective method for association prediction.

Materials and Methods {#S2}
=====================

Material {#S2.SS1}
--------

We download microbe-disease associations from HMDAD ([@B31]), which contains 483 verified associations' records between 292 microbes and 39 diseases. After removing the repetitive relationships, 450 distinct associations' records are obtained. Then we construct a 39 × 292 dimensional adjacency matrix *MD* of the associations' network. *MD* (*i*, *j*) is 1 indicating that there is a known association between disease *d*(*i*) and microbe *m*(*j*), otherwise, *MD* (*i*, *j*) is 0.

Methods {#S2.SS2}
-------

As illustrated in [Figure 1](#F1){ref-type="fig"}, firstly, the similarity networks for microbe and disease have been constructed. And then, a heterogeneous network integrating two similarity networks and microbe-disease associations' network can be obtained. After that, the embedding algorithm Node2vec is utilized to learn the representation for every node. Finally, according to the topology information based on Node2vec method, we calculate the relation score between every microbe vector and disease vector.

![The flowchart of LGRSH.](fmicb-11-00579-g001){#F1}

### Calculation of Microbe Similarities Based on the GIP Kernel Similarity {#S2.SS2.SSS1}

Based on the assumption that two microbes are more likely to share functional similarities potentially if they are related to more common diseases. We calculate the GIP kernel similarity for microbes based on known microbe-disease associations' network. For microbes *m(i)* and *m(j)*, the similarity score is obtained according to Eq. (1) ([@B53]):
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where *m(i, j)* represents two arbitrary microbes in matrix *MD*. Parameter γ*~*m*~* is used to control the bandwidth and is affected by a new bandwidth parameter γ*~*m*~'*([@B53]), which can be obtained as Eq. (2):
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here, *N*~*m*~ is equal to 292, which indicates the total number of microbes. The parameter γ*~*m*~'* is set to 1 for simplicity ([@B53]).

### Calculation of Disease Similarities Based on the GIP Kernel Similarity {#S2.SS2.SSS2}

In the similar way, we construct a disease similarity network by using the GIP kernel similarity for each disease pair. The similarity between disease *d(i)* and *d(j)* is obtained according to Eq. (3) ([@B53]):
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where *d(i, j)* represents two arbitrary diseases in matrix *MD*. The parameter γ*~*d*~* can be obtained as Eq. (4):
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here, *N*~*d*~ is equal to 39, which indicates the total number of diseases. The parameter γ*~*d*~'* is set to 1 for simplicity ([@B53]).

### Constructing a Heterogeneous Network for Microbes and Diseases {#S2.SS2.SSS3}

According to the Eqs (1) and (3), we have constructed two similarity matrices SM and SD. Then we construct a heterogeneous network including the edges of microbe--microbe, microbe-disease and disease--disease associations, and it can be expressed as Eq. (5):
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where *P* represents the matrix of heterogeneous network. *MD*^*T*^ is the transpose of *MD*.

### Using Node2vec to Learning Representations {#S2.SS2.SSS4}

Node2vec is a flexible neighborhood sampling strategy which can explore neighborhoods in the form of Breadth-First Sampling (*BFS*) and Depth-First Sampling (*DFS*) fashion by introducing two parameters ([@B19]). It maximizes the network neighborhood of nodes by mapping nodes to vector feature spaces. Therefore, we apply Node2vec to learn vector representations for nodes in the heterogeneous network.

Firstly, we utilize a bias random walk strategy to calculate the transition probabilities for every node. For a current node *u*, the probability of accessing the next node *x* can be calculated as follows:
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here, *Z* is a regularization constant. π*~*ux*~* is denormalized transition probabilities on edges (*u*, *x*) leading from *u*, which is influenced by a weight adjustment parameter α. We suppose the walk just went from *t* to *u* and setπ~*ux*~ = α~*pq*~(*t*, *x*)⋅*w*~*ux*~, where
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here, *d*~*tx*~ is in the range of {0, 1, 2}, representing the shortest distance from nodes *t* to *x*. Parameters *p* and *q* are used to strike a balance between *DFS* and *BFS*. As shown in [Figure 2](#F2){ref-type="fig"}, parameter *p* is a return parameter that affects the possibility of re-traversing a node immediately during a walk. If *p* is set to be larger, it is less likely to revisit the node that was just accessed. This strategy can lead to moderate exploration and avoid repetitive sampling. If the value is set to be smaller, the walk is more likely to backtrack, and tends to reach nodes near the node. There is more concerned for the local information. Parameter *q* is an in-out parameter, which allows searches to distinguish "inward" and "outward" nodes ([@B55]). If *q* \> 1, the walk tends to be closer to node *u*. In contrast, if *q* \< 1, it tends to traverse nodes far from node *u* ([@B55]).

![Description of walking strategy in Node2vec when the traversal has just gone from *t* to *u*.](fmicb-11-00579-g002){#F2}

We first select one node *u* and mark it as the current node, and then select one node *v* from all the neighbors of the current node *u* based on the transition probabilities calculated above. Following, we mark this newly selected node *v* as the current node and repetitive such as a node sampling process. The algorithm terminates when the number of nodes in a sequence reaches a preset walking length *l*. By referring to the previous paper, we set *l* as10 ([@B37]).

Node2vec uses Skip-gram model to generate eigenvectors of nodes ([@B24]). Skip-gram model is a word embedding algorithms for learning distributed vector representations from a large number of textual corpora which tries to categorize a word according to other words in the same sentence as much as possible ([@B36]). In fact, the sequence of nodes obtained by bias random walk algorithm, each node actually corresponds to a word. The input of this model is the sequence encoding of a node, and the output is the nodes before and after the sequence. In this paper, we set the context size to 10 and the dimension of these eigenvectors to 128 according to the original parameter selection for the best performance ([@B19]). The algorithm is detailed in [Figure 3](#F3){ref-type="fig"}.

![Description of algorithm Node2vec.](fmicb-11-00579-g003){#F3}

### Association Discovering {#S2.SS2.SSS5}

According to the popular rule-based inference method for predicting novel drug-target associations based on indirect relationships in 2017 ([@B58]), we utilize a modified Scoring mechanism to grade microbe-disease relations based on the low-dimensional vector representation. Considering that indirect relationships do not fully predict the relationship if there are few known relations between some microbes and diseases, especially if there is only single relationship, we have used both direct and indirect connections to calculate correlations between microbes and diseases.

We use *Score(m~*i*~, d~*j*~)* to represent the correlation score between the *ith* microbe and *jth* disease in the heterogeneous network. It can be calculated according to Eq. (8):
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In this Equation, *m* and *d* indicate the numbers of microbe and disease, *MD(i, j)* is the association between disease *i* and microbe *j*. The *Sim(u, v)* is calculated as Eq. (9):
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here, *d* represents the dimension for each vector, *u*~*k*~, *v*~*k*~ represent the components of vectors *u* and *v*.

Results {#S3}
=======

We implement LOOCV and fivefold cross validation on HMDAD to assess the prediction performance of LGRSH. In the LOOCV, we regard each known association as a test sample, with other known associations as training samples ([@B42]). All unverified microbe-disease associations are regarded as candidate samples. In the fivefold cross validation, we randomly divide all known microbe-disease associations into 5 average groups. Each of these five groups is regarded as testing sample, while other four groups are training samples. This process is conducted five times to mitigate the bias due to random sample partitioning ([@B38]). Based on the prediction score, we evaluate the predictive performance by ranking the test samples. The AUC can be calculated according to the receiver operating characteristic (ROC) curve. If there is a random prediction performance, the AUC value is 0.5.

Effect of Parameters {#S3.SS1}
--------------------

There are two important parameters in Node2vec. One is a return parameter *p* and another is an in-out parameter *q*. We set various values under the framework of fivefold cross validation in order to evaluate the impact of these parameters. According to the comparison results in [Table 1](#T1){ref-type="table"} and [Figure 4](#F4){ref-type="fig"}, we can find that the performance of LGRSH is best with 0.9254 while *p* = 0.5, *q* = 4. Hence, we set *p* = 0.5, *q* = 4 in the subsequent experiments.

###### 

Effect of parameters *p* and *q* in fivefold cross validation.

               *q* = 0.25   *q* = 0.5   *q* = 1   *q* = 2   *q* = 4      *q* = 8   *q* = 16
  ------------ ------------ ----------- --------- --------- ------------ --------- ----------
  *p* = 0.25   0.9251       0.9165      0.9178    0.9246    0.9229       0.9236    0.9244
  *p* = 0.5    0.9253       0.9236      0.9251    0.9246    **0.9254**   0.9235    0.9229
  *p* = 1      0.9240       0.9250      0.9190    0.9213    0.9234       0.9234    0.9242
  *p* = 2      0.9214       0.9204      0.9239    0.9230    0.9251       0.9181    0.9208
  *p* = 4      0.9215       0.9222      0.9206    0.9229    0.9241       0.9239    0.9235

Bold values: LGRSH achieves the best performance while

p

= 0.5,

q

= 4.

![Effect of parameters *p* and *q* in fivefold cross validation.](fmicb-11-00579-g004){#F4}

Comparison With Other Methods {#S3.SS2}
-----------------------------

We compare LGRSH with three methods including LRLSHMDA ([@B53]), KATZHMDA ([@B9]) and BiRWHMDA ([@B59]). These four methods are measured by Precision-recall curve. As illustrated in [Figures 5](#F5){ref-type="fig"}, [6](#F6){ref-type="fig"}, we can draw a conclusion that LGRSH performs better than other three methods.

![Prediction comparison between LGRSH and other three methods in LOOCV and fivefold cross validation while *p* = 0.5, *q* = 4.](fmicb-11-00579-g005){#F5}

![Precision-recall curves for LGRSH and other three methods in fivefold cross validation.](fmicb-11-00579-g006){#F6}

Furthermore, we measure the top-level results of LGRSH and three other methods in LOOCV. As shown in [Figure 7](#F7){ref-type="fig"}, LGRSH can find more known associations among the top 500 predicted microbes.

![The number of correctly predicted by LGRSH and other three methods on HMDAD.](fmicb-11-00579-g007){#F7}

Case Studies {#S4}
============

To evaluate the ability of LGRSH for discovering unknown associations in HMDAD, we implement case studies in asthma, COPD and IBD. We conduct experiments for 10 times on each diseases to make the results more stable. After calculating the similarity of every microbe and disease, the scores are sorted in descending order to obtain the top-10 candidate microbes for every disease. The scores of top-10 disease-related microbes are provided in [Supplementary Tables S1](#TS1){ref-type="supplementary-material"}--[S3](#TS3){ref-type="supplementary-material"}, respectively.

Asthma {#S4.SS1}
------

Asthma is a common inflammatory disease affecting more than 300 million people all over the world, which is more common in childhood with recurrent cough, wheezing and breathing difficulties. In recent years, asthma has been found to be closely linked with microbes ([@B4]). Hence, we consider Asthma for case studies. As shown in [Table 2](#T2){ref-type="table"}, 8 of top-10 discovered microbes were confirmed. For instance, Clostridium difficile colonization (ranked 1st in the list) in 1 month was associated with asthma between the ages of 6 and 7 ([@B51]). Researchers also proved that colonization with Clostridium coccoides (ranked 3rd in the list) and Bacteroides (ranked 7th in the list) at 3 weeks were associated with positive predictors of asthma at age 3 ([@B7], [@B6]). In addition, the abundance of Firmicutes (ranked 2nd in the list) and Enterobacteriaceae (ranked 5th in the list) were higher in severe asthmatics compared with non-asthmatic people, while Actinobacteria (ranked 4th in the list) and Lachnospiraceae (ranked 9th in the list) with lower proportion ([@B34]; [@B10]; [@B56]; [@B29]). Moreover, [@B21] found that Lactobacillus (ranked 6th in the list) can reduce asthma severity and improve asthma control, which is beneficial to children with asthma.

###### 

Validation results for Top-10 predicted microbes related with asthma.

  Rank   Microbe                 Evidence
  ------ ----------------------- -----------------
  1      Clostridium difficile   PMID:21872915
  2      Firmicutes              PMID:27078029
  3      Clostridium coccoides   PMID:21477358
  4      Actinobacteria          PMID:30286807
  5      Enterobacteriaceae      PMID:28947029
  6      Lactobacillus           PMID:30400588
  7      Bacteroides             PMID:18822123
                                 PMID:29161087
  8      Burkholderia            **Unconfirmed**
  9      Lachnospiraceae         PMID:28912020
  10     Enterococcus            **Unconfirmed**

Chronic obstructive pulmonary disease (COPD) {#S4.SS2}
--------------------------------------------

Chronic obstructive pulmonary disease is a progressive obstructive pulmonary disease with main symptoms of breathing difficultly and coughing ([@B43]). It is more common among smokers, and is also influenced by factors like air pollution and genetics. Although the disease can be slowed down by treatment, there is still no clear treatment or pathogenesis for it. Recently, some findings indicate that changes in microbes may have significant effects in the development of COPD ([@B32]). Thus, we consider COPD for case studies. As shown in [Table 3](#T3){ref-type="table"}, 8 of top 10 discovered microbes were confirmed. For example, the main flora of Proteobacteria (ranked 1st in the list) and Bacteroidetes (ranked 5th in the list) increased with the deterioration of COPD ([@B44]). Researchers also found that Helicobacter pylori (ranked 3rd in the list) infection is associated with reduced lung function and systemic inflammation in COPD patients ([@B33]). In patients with COPD, the proportion of Prevotella (ranked 2nd in the list) is reduced compared with healthy people, but phyla Actinobacteria (ranked 4th in the list), Clostridium difficile (ranked 6th in the list) and Lactobacillus (ranked 8th in the list) are increased ([@B54]; [@B26]; [@B13]; [@B16]). For example, the Clostridium difficile is twice as high in COPD patients as in healthy person. Moreover, Staphylococcus aureus (ranked 10th in the list) has been found in the respiratory tract of patients with COPD ([@B50]).

###### 

Validation results for Top-10 predicted microbes related with COPD.

  Rank   Microbe                 Evidence
  ------ ----------------------- -----------------
  1      Proteobacteria          PMID:29579057
  2      Prevotella              PMID:28542929
  3      Helicobacter pylori     PMID:28558695
  4      Actinobacteria          PMID:29709671
  5      Bacteroidetes           PMID:29579057
  6      Clostridium difficile   PMID:30430993
  7      Clostridium coccoides   **Unconfirmed**
  8      Lactobacillus           PMID:26630356
  9      Lachnospiraceae         **Unconfirmed**
  10     Staphylococcus aureus   PMID:30804927

Inflammatory bowel disease (IBD) {#S4.SS3}
--------------------------------

Inflammatory bowel disease is a chronic, idiopathic gastrointestinal inflammatory disease that is thought to be influenced by environmental and host factors ([@B12]). It is characterized by recurrent episodes, diverse clinical manifestations and severe complications such as bleeding, abscess formation and perforation ([@B11]). In this paper, we consider IBD for case studies. As shown in [Table 4](#T4){ref-type="table"}, 10 of top-10 discovered microbes were confirmed. For instance, researchers have found that IBD is related to gut microbiological disorders including expansion of Enterobacteriaceae facultative anaerobic bacteria (ranked 8th in the list) and decrease in some beneficial fecal bacteria such as Firmicutes (ranked 5th in the list) ([@B14]; [@B60]). In patients with IBD, the dominant of Prevotella (ranked 1st in the list), Veillonella (ranked 9th in the list) and Haemophilus (ranked 10th in the list) were largely contribute to dysbiosis ([@B46]). Bacteroidetes (ranked second in the list) and Lactobacillus (ranked 7th in the list) were significantly increased compared with healthy people, but the Clostridium coccoides (ranked 6th in the list) was less abundant ([@B47]; [@B49]; [@B14]). Researchers also found that Clostridium difficile (ranked 3rd in the list) infection has become a significant clinical challenge for patients suffering from IBD, which can worsen flares of IBD, inducing to emergent colectomies and mortality ([@B20]). Moreover, recent experimental results found that chronic infection with Helicobacter pylori (ranked 4th in the list) is protective against IBD. And IBD patients are least likely to be infected with Helicobacter pylori compared to the normal population ([@B48]; [@B25]).

###### 

Validation results for Top-10 predicted microbes related with IBD.

  Rank   Microbe                 Evidence
  ------ ----------------------- ---------------
  1      Prevotella              PMID:24013298
  2      Bacteroidetes           PMID:29492876
  3      Clostridium difficile   PMID:24838421
  4      Helicobacter pylori     PMID:22221289
                                 PMID:28124160
  5      Firmicutes              PMID:25307765
                                 PMID:29492876
  6      Clostridium coccoides   PMID:19235886
  7      Lactobacillus           PMID:26340825
  8      Enterobacteriaceae      PMID:30319571
  9      Veillonella             PMID:30573380
  10     Haemophilus             PMID:24013298

Conclusion {#S5}
==========

There are countless microbe communities inhabited in the human body, having important impacts on human health and disease by regulating the metabolism and immunity. With the establishment of relational databases for microbes and diseases, exploring their associations have become a hot topic for researchers. In this study, we propose a predictive approach called LGRSH by utilizing network embedding algorithm Node2vec to obtain the representation for every node in the heterogeneous network. According to the vector representation for every node, we rank the relevance of each microbe vector and disease vector to discover potential microbe-disease associations. In LOOCV and 5-fold cross validation, LGRSH performs better compared with three other methods with AUC reached 0.9260 and 0.9254. The case studies of asthma, COPD and IBD show that LGRSH can be used as a predictive tool for microbe-disease associations.

Certainly, there are still some deficiencies in LGRSH. For example, there are only 450 know micro-disease associations, which accounts for very small proportion of human microbial diseases. This may result in less comprehensive for prediction. We believe that the problem will be solved when more microbe-disease links are discovered. In addition, the embedding algorithm itself is a local method. In the future, we will learn more graph representation algorithms to improve the global capability. Moreover, we calculate the similarities for microbe and disease through the GIP kernel, which may biased toward microbes and diseases with more known associations. Hence, we will improve the efficiency of LGRSH by integrating some optimization strategies such as microbe functional similarity, disease semantic similarity and symptom-based disease similarity in the future work.
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